TOPLINE:
Clients with type 2 diabetes, obese, or weight problems taking the glucagon-like peptide 1 receptor agonist (GLP-1 RA) semaglutide appear to have actually an increased threat for an unusual condition that can trigger vision loss.
METHOD:
- Scientist performed a retrospective research study of 16,827 clients at Massachusetts Eye and Ear in Boston.
- Their analysis concentrated on 710 clients with type 2 diabetes (194 of whom had actually been recommended semaglutide) and 979 clients with obese or weight problems (361 recommended semaglutide).
- The scientists compared clients recommended semaglutide with those recommended a medication besides a GLP-1 representative. They matched clients by elements such as age and sex and whether they had high blood pressure, obstructive sleep apnea, or coronary artery illness.
- They evaluated the cumulative occurrence of nonarteritic anterior ischemic optic neuropathy (NAION) throughout 36 months of follow-up.
TAKEAWAY:
- Semaglutide usage was related to a greater threat for NAION in clients with type 2 diabetes (threat ratio [HR]4.28; 95% CI, 1.62-11.29).
- In clients with obese or weight problems, semaglutide once again was connected to a greater threat for NAION (HR, 7.64; 95% CI, 2.21-26.36).
- Amongst clients with type 2 diabetes, the cumulative occurrence of NAION over 36 months was 8.9% for those recommended semaglutide vs 1.8% amongst those taking non– GLP-1 medications.
- For clients with obese or weight problems, the cumulative occurrence of NAION over 36 months was 6.7% for the semaglutide friend vs 0.8% for those in the other group.
IN PRACTICE:
Semaglutide has actually “supplied extremely substantial advantages in lots of methods, however future conversations in between a client and their doctor ought to consist of NAION as a possible threat,” research study leader Joseph Rizzo, MD, with Mass Eye and Ear and Harvard Medical School, stated in a press release about the findings. “It is very important to value, nevertheless, that the increased threat connects to a condition that is fairly unusual.”
“Given the varieties of individuals who have actually been hired to scientific trials and the a great deal of individuals internationally who utilize GLP-1 RAs, we must be positive that if supported, the outright threat of establishing NAION in direct relation to taking semaglutide needs to undoubtedly be uncommon,” Susan P. Mollan, MBcHB, of University Hospitals Birmingham NHS Foundation Trust, in England, composed in a commentary released with the research study.
SOURCE:
The research study was released online on July 3 in JAMA Ophthalmology
RESTRICTIONS:
The clients were seen at a health center that concentrates on ophthalmology and has a customized neuro-ophthalmology service, so the outcomes might not completely use to other settings. The outcomes were driven by a reasonably little number of NAION cases in the clients exposed to semaglutide. The research study does not develop that semaglutide straight triggers NAION, the scientists kept in mind. “The finest techniques to verify, refute, or fine-tune our findings would be to perform a much bigger, retrospective, multicenter population-based friend research study; a potential, randomized scientific research study; or a postmarket analysis of all GLP-1 RA drugs,” they composed.
